Comparative Pharmacology
Head-to-head clinical analysis: ACTICORT versus ARISTOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICORT versus ARISTOCORT.
ACTICORT vs ARISTOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Glucocorticoid receptor agonist; suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; modulates gene expression and immune cell activity.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
Intramuscular: 40-80 mg every 2-4 weeks; Intra-articular: 5-40 mg depending on joint size; Intralesional: 2.5-25 mg; Oral: 4-12 mg/day divided every 6-12 hours.
None Documented
None Documented
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Plasma: 1-2 hours (triamcinolone); tissue half-life 18-36 hours due to receptor binding and slow release from tissues.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal elimination minor.
Category C
Category C
Corticosteroid
Corticosteroid